STATEMENT OF NEED

Dedifferentiated liposarcoma is an aggressive subtype of soft tissue sarcoma. Detection of MDM2 and/or CDK4 amplification distinguishes dedifferentiated liposarcoma from other types of undifferentiated sarcomas. Diagnosis of dedifferentiated liposarcoma remains challenging due to its complex karyotypes, quantitative genomic profiles, and pleomorphic pathological features (Nishio et al, 2021; Shen et al, 2022). Currently, surgical resection with or without radiation is the mainstay of treatment for localized disease, and anthracycline-based therapy is a standard first-line treatment for advanced disease. Numerous novel therapies are currently under investigation, including CDK4/6 inhibitors, MDM2-p53 pathway inhibitors, and immunotherapies, with the potential to transform the treatment landscape for dedifferentiated liposarcoma (Nishio et al, 2021). Due to the complex management of dedifferentiated liposarcoma, collaboration of the multidisciplinary health care team, including medical oncologists, surgical oncologists, radiation oncologists, and pathologists, is crucial. This Dedifferentiated Liposarcoma Task Force will provide a consensus opinion on the optimal diagnosis, treatment, and management of this disease. The Task Force includes co-chairs Richard F. Riedel, MD, Associate Professor in the Division of Medical Oncology at Duke University Medical Center, and Candace L. Haddox, MD, Physician at Dana-Farber Cancer Institute and Instructor in Medicine at Harvard Medical School; and faculty members Elizabeth H. Baldini, MD, MPH, FASTRO, Professor of Radiation Oncology at Brigham & Women’s Hospital, Dana-Farber Cancer Institute, and Harvard Medical School; Jason L. Hornick, MD, PhD, Professor of Pathology at Brigham and Women’s Hospital and Harvard Medical School; Vicki L. Keedy, MD, MSCI, Associate Professor of Medicine and Clinical Director of Sarcoma at Vanderbilt-Ingram Cancer Center; and Christina L. Roland, MD, MS, FACS, Associate Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center.

TARGET AUDIENCE

Medical oncologists, surgical oncologists, pathologists, radiation oncologists, orthopedic oncologists, nurse practitioners, physician assistants/associates and other health care professionals involved in the treatment of patients with soft tissue sarcoma.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to

• Summarize the key clinical, histopathologic, and genomic characteristics that make dedifferentiated liposarcoma unique from other soft tissue sarcoma subtypes
• Assess the benefits and limitations of current molecular testing methodologies for the characterization of soft tissue sarcomas
• Appreciate the role of a multimodality approach in the management of localized dedifferentiated liposarcoma, as well as the current systemic therapy landscape for patients with advanced disease
• Evaluate potential emerging therapies, including MDM2-p53 pathway inhibitors, CDK4/6 inhibitors, and immunotherapeutic approaches, for the treatment of dedifferentiated liposarcoma

REGISTRATION

There is no fee to view this live presentation.

COMMERCIAL SUPPORT

This Program was made possible, in part, by an independent grant from Boehringer Ingelheim Pharmaceuticals, Inc. who provided financial support for the Program. The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE) and were fully responsible for all aspects of the Program and publication development.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with ineligible companies that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Richard F. Riedel, MD, discloses that he has received grants/research support from Aadi Bioscience, AROG, Ayala, BioAtla, Blueprint, Cogent, Daiichi-Sankyo, Deciphera, GlaxoSmithKline, InhibRx, NanoCarrier, Oncternal, PTC Therapeutics, SARC, SpringWorks, TRACON, and Trillium; and that he has served as a consultant or on an advisory board/panel for Aadi Bioscience, Adaptimmune, Bayer, Blueprint, Boehringer Inhelheim, Daiichi-Sankyo, Decipheral, GlaxoSmithKline, NanoCarrier, and SpringWorks.

Candace L. Haddox, MD, discloses that she has served as a consultant or on an advisory/board panel for Aadi Bioscience; and that she has received grants/research support from Aadi Bioscience, EMD Serono, Cogent, HiFiBio, Roche, and Tango Therapeutics.

Elizabeth H Baldini, MD, MPH, FASTRO, has no relevant financial relationships to disclose.

Jason L. Hornick, MD, PhD, discloses that he has served as a consultant for Aadi Bioscience, Adaptimmune, and TRACON.

Vicki L. Keedy, MD, MSCI, discloses that she has served on an advisory board or panel for Deciphera and Epizyme; and that she has received grants/research support from Adaptimmune, Advenchen, Boehringer Ingelheim, Deciphera, Plexxikon, Shanghai Pharmaceuticals, and TRACON.

Christina L. Roland, MD, MS, FACS, has no relevant financial relationships to disclose. 

i3 Health has mitigated all relevant financial relationships.